Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 116
Filter
Add more filters

Publication year range
1.
Nature ; 574(7779): 581-585, 2019 10.
Article in English | MEDLINE | ID: mdl-31645725

ABSTRACT

The tricarboxylic acid cycle intermediate succinate is involved in metabolic processes and plays a crucial role in the homeostasis of mitochondrial reactive oxygen species1. The receptor responsible for succinate signalling, SUCNR1 (also known as GPR91), is a member of the G-protein-coupled-receptor family2 and links succinate signalling to renin-induced hypertension, retinal angiogenesis and inflammation3-5. Because SUCNR1 senses succinate as an immunological danger signal6-which has relevance for diseases including ulcerative colitis, liver fibrosis7, diabetes and rheumatoid arthritis3,8-it is of interest as a therapeutic target. Here we report the high-resolution crystal structure of rat SUCNR1 in complex with an intracellular binding nanobody in the inactive conformation. Structure-based mutagenesis and radioligand-binding studies, in conjunction with molecular modelling, identified key residues for species-selective antagonist binding and enabled the determination of the high-resolution crystal structure of a humanized rat SUCNR1 in complex with a high-affinity, human-selective antagonist denoted NF-56-EJ40. We anticipate that these structural insights into the architecture of the succinate receptor and its antagonist selectivity will enable structure-based drug discovery and will further help to elucidate the function of SUCNR1 in vitro and in vivo.


Subject(s)
Biphenyl Compounds/chemistry , Biphenyl Compounds/pharmacology , Piperazines/chemistry , Piperazines/pharmacology , Receptors, G-Protein-Coupled/antagonists & inhibitors , Receptors, G-Protein-Coupled/chemistry , Animals , Apoproteins/antagonists & inhibitors , Apoproteins/chemistry , Apoproteins/metabolism , Crystallography, X-Ray , Humans , Models, Molecular , Rats , Receptors, G-Protein-Coupled/metabolism , Receptors, Purinergic P2Y1/chemistry , Signal Transduction , Single-Domain Antibodies/chemistry , Species Specificity , Succinic Acid/metabolism
2.
Nano Lett ; 24(30): 9276-9282, 2024 Jul 31.
Article in English | MEDLINE | ID: mdl-39018419

ABSTRACT

The chirality transfer phenomenon is attractive for enhancing the optical functionality of nanomaterials by inducing sensitivity to the circular polarization states of photons. An underexplored aspect is how material properties of the achiral semiconductor impact the induced chiroptical signatures. Here we apply atomistic time-dependent density functional theory simulations to investigate the material properties that influence the chiroptical signatures of a lead halide perovskite nanocrystal with a chiral molecule bound to the surface. First, we find that both lattice disorder created by surface strain and halide substitution can increase the chiroptical response of the perovskite quantum dots by an order of magnitude. Both phenomena are attributed to a broadening of the density of the electronically excited states. Second, the intensity of the anisotropy spectra decreases with increasing dot size with a power law decay. Overall, these insights can be used to help guide experimental realization of highly resolvable polarized optical features in semiconducting nanomaterials.

3.
Clin Infect Dis ; 2024 Aug 02.
Article in English | MEDLINE | ID: mdl-39093815

ABSTRACT

BACKGROUND: Human parechovirus (HPeV) infection can result in severe disease in infants, including sepsis, seizures, brain injury, and death. In 2022, a resurgence of HPeV was noted in young infants. Spectrum of illness and outcomes remain to be fully described. METHODS: A multi-state retrospective cohort study was conducted to evaluate hospitalizations and outcomes of infants aged ≤6 months admitted in 2022 with laboratory-confirmed HPeV infection. Infants with severe disease were defined as having clinical seizures, or abnormalities on MRI or EEG during admission. Infants with severe vs non-severe disease were compared using descriptive statistics. RESULTS: 124 U.S. infants were identified with HPeV in 11 states. Cases of HPeV peaked in May and presented at a median of 25.8 days of life (0-194 d) with fever, fussiness, and poor feeding. Bacterial and other viral co-infections were rare. 33 (27%) of infants had severe neurologic disease, were more likely to present at an earlier age (13.9 vs 30 days of life, p<0.01), have preterm gestation (12% vs. 1%, p = 0.02), and present with respiratory symptoms (26% vs. 8%, p = 0.01) or apnea (41% vs. 1%, p <0.001). Subcortical white matter cytoxic cerebral edema was common in severe cases. Two infants with HPeV died during admission with severe neurologic HPeV disease; no infant with mild HPeV disease died. CONCLUSIONS: This is the largest, geographically-diverse U.S. study to describe the 2022 HPeV outbreak among infants. Longitudinal follow up of infants is needed to define predictors and outcomes of severe HPeV disease.

4.
Blood ; 139(14): 2227-2239, 2022 04 07.
Article in English | MEDLINE | ID: mdl-35051265

ABSTRACT

The process of platelet production has so far been understood to be a 2-stage process: megakaryocyte maturation from hematopoietic stem cells followed by proplatelet formation, with each phase regulating the peripheral blood platelet count. Proplatelet formation releases into the bloodstream beads-on-a-string preplatelets, which undergo fission into mature platelets. For the first time, we show that preplatelet maturation is a third, tightly regulated, critical process akin to cytokinesis that regulates platelet count. We show that deficiency in cytokine receptor-like factor 3 (CRLF3) in mice leads to an isolated and sustained 25% to 48% reduction in the platelet count without any effect on other blood cell lineages. We show that Crlf3-/- preplatelets have increased microtubule stability, possibly because of increased microtubule glutamylation via the interaction of CRLF3 with key members of the Hippo pathway. Using a mouse model of JAK2 V617F essential thrombocythemia, we show that a lack of CRLF3 leads to long-term lineage-specific normalization of the platelet count. We thereby postulate that targeting CRLF3 has therapeutic potential for treatment of thrombocythemia.


Subject(s)
Blood Platelets , Thrombocythemia, Essential , Blood Platelets/metabolism , Humans , Megakaryocytes/metabolism , Microtubules , Platelet Count , Receptors, Cytokine , Thrombocythemia, Essential/drug therapy , Thrombopoiesis/genetics
5.
J Vasc Surg ; 2024 Aug 29.
Article in English | MEDLINE | ID: mdl-39216612

ABSTRACT

OBJECTIVE: Popliteal access (PA) as an alternative to conventional femoral access has not been reported in the office-based catheter laboratory setting (OBL) and may be perceived to have higher risks. The purpose of this study is to evaluate the safety and efficacy of popliteal access for endovascular treatment of iliofemoral arterial occlusive disease in an OBL setting. METHODS: From 10/2018 - 10/2023 a total of 1,408 PAD interventions were performed in our OBL. A cohort of 27 popliteal access consecutive procedures for femoral and iliac artery occlusions were studied. All interventions were done using a micro-puncture needle under ultrasound guidance. All patients were discharged 1 hour after completion of the procedure. Indications for popliteal access were presence of aortoiliac stent/grafts, aorto-bifemoral or aortoiliac bypasses, difficult contralateral or antegrade femoral access, and flush superficial femoral artery (SFA) occlusions. Procedures were determined to be successful upon complete resolution of the target lesions and safety was measured peri-operatively and at 90-days. Patency was determined clinically, by arterial duplex, and by need for reintervention up to 2 years. RESULTS: 27 popliteal access procedures were performed in 25 patients (21 complete femoral artery occlusions, 6 severe stenosis). Iliac disease was present in 9. Indications for PA were existing aortoiliac stent graft 11, aorto-bifem-iliac bypass 4, non-crossable iliac occlusions 3, failed antegrade femoral access 4, flush SFA occlusion 3, and bilateral common femoral artery disease precluding access 2. TASC pre-op was B: 4, C: 4, D:19. Treatments included atherectomy/balloon angioplasty (BA) and stent 12, BA and stenting 4, atherectomy/BA 5, BA alone 6. Successful opening of occlusions occurred in 25/27 (92.5%). No complications or major adverse cardiac events (MACE) occurred except 1 asymptomatic small popliteal AV fistula. Of the 25 successful procedures duplex patency at 3, 6 & 12 months was 19/20 (95%), 11/15 (69.3%) & 11/13 (61%). Rutherford Classification improved from pre-op > 4 in 24/27 (89%) to post-op < 2 at 1 month in 23/23 (100%), 3 months in 19/20 (95%), 6 months in 11/15 (69.3%), 12 months in 11/13 (61%). Freedom from re-intervention at 3 months in 19/20 (95%), 6 months in 13/15 (86%), and 12 months in 12/13 (79%). CONCLUSIONS: Popliteal artery access for complex iliofemoral disease is safe and effective and should be considered as a valid alternative option in the OBL setting.

6.
Proc Natl Acad Sci U S A ; 116(16): 7926-7931, 2019 04 16.
Article in English | MEDLINE | ID: mdl-30926668

ABSTRACT

Dysregulation of the alternative complement pathway (AP) predisposes individuals to a number of diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and C3 glomerulopathy. Moreover, glomerular Ig deposits can lead to complement-driven nephropathies. Here we describe the discovery of a highly potent, reversible, and selective small-molecule inhibitor of factor B, a serine protease that drives the central amplification loop of the AP. Oral administration of the inhibitor prevents KRN-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats. In addition, inhibition of factor B prevents complement activation in sera from C3 glomerulopathy patients and the hemolysis of human PNH erythrocytes. These data demonstrate the potential therapeutic value of using a factor B inhibitor for systemic treatment of complement-mediated diseases and provide a basis for its clinical development.


Subject(s)
Complement Factor B/antagonists & inhibitors , Complement Pathway, Alternative/drug effects , Drug Discovery/methods , Immunologic Factors/pharmacology , Animals , Disease Models, Animal , Glomerulonephritis, Membranous/physiopathology , Humans , Male , Mice , Mice, Inbred C57BL , Rats, Sprague-Dawley
7.
Paediatr Anaesth ; 31(5): 613-615, 2021 05.
Article in English | MEDLINE | ID: mdl-33570775

ABSTRACT

A 4-day-old, 3.3 kg infant presented with suspected intestinal malrotation, necessitating emergent diagnostic laparoscopy. Intra-operatively, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) came back positive. This is the first case report of emergency surgery and anesthesia in a positive SARS-CoV-2 newborn. This report highlights a neonate with an incidental positive SARS-CoV-2 test, no known exposure history, negative polymerase chain reaction maternal testing, and absence of respiratory symptoms who required modified pressure control ventilation settings to adequately ventilate with the high-efficiency particulate air filter in situ.


Subject(s)
COVID-19 Testing/methods , COVID-19/diagnosis , Digestive System Abnormalities/surgery , Intestinal Volvulus/surgery , SARS-CoV-2 , Humans , Infant, Newborn
8.
Eur Respir J ; 55(3)2020 03.
Article in English | MEDLINE | ID: mdl-31949113

ABSTRACT

Sarcoidosis is a disease characterised by granuloma formation. There is an unmet need for new treatment strategies beyond corticosteroids. The NLRP3 inflammasome pathway is expressed in innate immune cells and senses danger signals to elicit inflammatory interleukin (IL)-1ß; it has recently become a druggable target. This prompted us to test the role of the NLRP3 inflammasome and IL-1ß pathway in granuloma formation and sarcoidosis.19 sarcoid patients and 19 healthy volunteers were recruited into this pilot study. NLRP3 inflammasome activity was measured in bronchoalveolar lavage (BAL) cells and lung and skin biopsies using immunohistochemistry, Western blot, reverse-transcriptase PCR and ELISA. For in vivo experiments we used the trehalose 6,6'-dimycolate-granuloma mouse model and evaluated lung granuloma burden in miR-223 knockout and NLRP3 knockout mice, as well as the treatment effects of MCC950 and anti-IL-1ß antibody therapy.We found strong upregulation of the NLRP3 inflammasome pathway, evidenced by expression of activated NLRP3 inflammasome components, including cleaved caspase-1 and IL-1ß in lung granuloma, and increased IL-1ß release of BAL cells from sarcoid patients compared to healthy volunteers (p=0.006). mRNA levels of miR-223, a micro-RNA downregulating NLRP3, were decreased and NLRP3 mRNA correspondingly increased in alveolar macrophages from sarcoid patients (p<0.005). NLRP3 knockout mice showed decreased and miR-223 knockout mice increased granuloma formation compared to wild-type mice. Pharmacological interference using NLRP3 pathway inhibitor MCC950 or an anti-IL-1ß antibody resulted in reduced granuloma formation (p<0.02).In conclusion, our data provide evidence of upregulated inflammasome and IL-1ß pathway activation in sarcoidosis and suggest both as valid therapeutic targets.


Subject(s)
Granuloma , Inflammasomes , NLR Family, Pyrin Domain-Containing 3 Protein , Sarcoidosis , Animals , Caspase 1 , Humans , Interleukin-1beta , Mice , NLR Family, Pyrin Domain-Containing 3 Protein/genetics , Pilot Projects
9.
J Pediatr Hematol Oncol ; 42(5): e365-e368, 2020 07.
Article in English | MEDLINE | ID: mdl-31033783

ABSTRACT

Leukemia-predisposing conditions, such as GATA2 haploinsufficiency, are known for their high penetrance and expressivity profiles. These disorders pose a difficult diagnostic challenge to even the most experienced clinician when they first present. We describe the case of a 17-year-old male presenting with features of nontuberculous mycobacterial infection, pulmonary fibrinoid granulomatous vasculitis, and myelodysplasia in the setting of a pathogenic GATA2 frameshift mutation confirmed by next-generation sequencing. The broad differential for GATA2 haploinsufficiency requires prompt recognition of key clinical features and laboratory abnormalities towards directing diagnosis and guiding appropriate and perhaps life-saving therapy.


Subject(s)
Fever of Unknown Origin/complications , Frameshift Mutation , GATA2 Deficiency/complications , GATA2 Transcription Factor/genetics , Haploinsufficiency , Myelodysplastic Syndromes/pathology , Adolescent , Female , Fever of Unknown Origin/genetics , GATA2 Deficiency/genetics , Humans , Myelodysplastic Syndromes/etiology , Prognosis
10.
Bioethics ; 34(7): 687-694, 2020 09.
Article in English | MEDLINE | ID: mdl-32562283

ABSTRACT

In 2017 and 2018, the English courts were asked to decide whether continued life-sustaining treatment was in the best interests of three infants: Charlie Gard, Alfie Evans and Isaiah Haastrup. Each infant had sustained catastrophic, irrecoverable brain damage. Dignity played an important role in the best interests assessments reached by the Family division of the High Court in each case. Multiple conceptions of dignity circulate, with potentially conflicting implications for infants such as Charlie, Alfie and Isaiah. The judgements do not explicate the conceptions of dignity upon which they rely. This article reconstructs the conceptions of dignity invoked in these judgements, finding that a broadly Kantian, agential conception dominates, under which human dignity requires the prospect of agency. This conception is situated within the broader body of thought on dignity, and the potentially adverse implications of applying the reconstructed conception in best interests assessments for infants with severely restricted consciousness are discussed.


Subject(s)
Ethical Analysis , Life Support Care/ethics , Life Support Care/legislation & jurisprudence , Moral Status , Respect , Withholding Treatment/ethics , Withholding Treatment/legislation & jurisprudence , England , Humans , Infant , Jurisprudence , Male , Medical Futility/ethics , Medical Futility/legislation & jurisprudence
11.
Article in English | MEDLINE | ID: mdl-32863890

ABSTRACT

Up to 85% of the US adult population carries herpes simplex virus type-1 (HSV-1), with a smaller percentage (22%) infected with HSV-2. Herpesviruses can survive in lytic phase, when the viruses are actively replicating, or in latency, when the virus is functionally dormant in ganglia. Among drugs to treat these infections is acyclovir (ACV). ACV exhibits poor oral bioavailability and a short in vivo half-life; only about 10-15% of ingested drug enters the bloodstream and its half-life is about 3 hours. With those disadvantages and the possibility of poor patient compliance, viral replication may not always be suppressed. To abrogate these shortcomings we propose local distribution via sustained drug release. We present a matrix-based antiherpetic ring, composed of poly(ethylene co-vinyl acetate), that releases ACV directly to the vaginal epithelium. A 30-day in vitro drug release trial showed that approximately 135 +/- 20 µg/day of ACV was consistently released. Rings were nontoxic in cell culture and suppressed primary HSV-1 and HSV-2 replication. We expect these data form the basis for novel interventions in human health, where new prophylactics and therapeutics against genital herpes are truly needed.

12.
Mol Biol Evol ; 34(7): 1613-1628, 2017 07 01.
Article in English | MEDLINE | ID: mdl-28369510

ABSTRACT

TYRO3, AXL, and MERTK (TAM) receptors are a family of receptor tyrosine kinases that maintain homeostasis through the clearance of apoptotic cells, and when defective, contribute to chronic inflammatory and autoimmune diseases such as atherosclerosis, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, and Crohn's disease. In addition, certain enveloped viruses utilize TAM receptors for immune evasion and entry into host cells, with several viruses preferentially hijacking MERTK for these purposes. Despite the biological importance of TAM receptors, little is understood of their recent evolution and its impact on their function. Using evolutionary analysis of primate TAM receptor sequences, we identified strong, recent positive selection in MERTK's signal peptide and transmembrane domain that was absent from TYRO3 and AXL. Reconstruction of hominid and primate ancestral MERTK sequences revealed three nonsynonymous single nucleotide polymorphisms in the human MERTK signal peptide, with a G14C mutation resulting in a predicted non-B DNA cruciform motif, producing a significant decrease in MERTK expression with no significant effect on MERTK trafficking or half-life. Reconstruction of MERTK's transmembrane domain identified three amino acid substitutions and four amino acid insertions in humans, which led to significantly higher levels of self-clustering through the creation of a new interaction motif. This clustering counteracted the effect of the signal peptide mutations through enhancing MERTK avidity, whereas the lower MERTK expression led to reduced binding of Ebola virus-like particles. The decreased MERTK expression counterbalanced by increased avidity is consistent with antagonistic coevolution to evade viral hijacking of MERTK.


Subject(s)
Proto-Oncogene Proteins/genetics , Receptor Protein-Tyrosine Kinases/genetics , Animals , Apoptosis/genetics , Base Sequence/genetics , Cell Movement , Evolution, Molecular , Homeostasis , Humans , Phylogeny , Polymorphism, Single Nucleotide/genetics , Primates/genetics , Protein-Tyrosine Kinases , Proto-Oncogene Proteins/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Signal Transduction , Silent Mutation/genetics , c-Mer Tyrosine Kinase , Axl Receptor Tyrosine Kinase
13.
Blood ; 127(9): e1-e11, 2016 Mar 03.
Article in English | MEDLINE | ID: mdl-26660425

ABSTRACT

In platelets, splicing and translation occur in the absence of a nucleus. However, the integrity and stability of mRNAs derived from megakaryocyte progenitor cells remain poorly quantified on a transcriptome-wide level. As circular RNAs (circRNAs) are resistant to degradation by exonucleases, their abundance relative to linear RNAs can be used as a surrogate marker for mRNA stability in the absence of transcription. Here we show that circRNAs are enriched in human platelets 17- to 188-fold relative to nucleated tissues and 14- to 26-fold relative to samples digested with RNAse R to selectively remove linear RNA. We compare RNAseq read depths inside and outside circRNAs to provide in silico evidence of transcript circularity, show that exons within circRNAs are enriched on average 12.7 times in platelets relative to nucleated tissues and identify 3162 genes significantly enriched for circRNAs, including some where all RNAseq reads appear to be derived from circular molecules. We also confirm that this is a feature of other anucleate cells through transcriptome sequencing of mature erythrocytes, demonstrate that circRNAs are not enriched in cultured megakaryocytes, and demonstrate that linear RNAs decay more rapidly than circRNAs in platelet preparations. Collectively, these results suggest that circulating platelets have lost >90% of their progenitor mRNAs and that translation in platelets occurs against the backdrop of a highly degraded transcriptome. Finally, we find that transcripts previously classified as products of reverse transcriptase template switching are both enriched in platelets and resistant to decay, countering the recent suggestion that up to 50% of rearranged RNAs are artifacts.


Subject(s)
Blood Platelets/metabolism , RNA Stability/genetics , RNA/genetics , Transcriptome/genetics , Exons/genetics , Exoribonucleases/metabolism , Humans , Megakaryocytes/metabolism , RNA, Circular , Real-Time Polymerase Chain Reaction , Reproducibility of Results
14.
Angew Chem Int Ed Engl ; 57(46): 15128-15132, 2018 11 12.
Article in English | MEDLINE | ID: mdl-30272384

ABSTRACT

The power of the Cloud has been harnessed for pharmaceutical compound production with remote servers based in Tokyo, Japan being left to autonomously find optimal synthesis conditions for three active pharmaceutical ingredients (APIs) in laboratories in Cambridge, UK. A researcher located in Los Angeles, USA controlled the entire process via an internet connection. The constituent synthetic steps for Tramadol, Lidocaine, and Bupropion were thus optimized with minimal intervention from operators within hours, yielding conditions satisfying customizable evaluation functions for all examples.


Subject(s)
Analgesics, Opioid/chemical synthesis , Anesthetics, Local/chemical synthesis , Antidepressive Agents, Second-Generation/chemical synthesis , Bupropion/chemical synthesis , Chemistry Techniques, Synthetic/methods , Lidocaine/chemical synthesis , Tramadol/chemical synthesis , Chemistry Techniques, Synthetic/economics , Chemistry Techniques, Synthetic/instrumentation , Cloud Computing/economics , Drug Industry/economics , Drug Industry/instrumentation , Drug Industry/methods , Equipment Design , Japan , United Kingdom , United States
15.
Bioorg Med Chem ; 25(16): 4512-4525, 2017 08 15.
Article in English | MEDLINE | ID: mdl-28689977

ABSTRACT

GPR4, a G-protein coupled receptor, functions as a proton sensor being activated by extracellular acidic pH and has been implicated in playing a key role in acidosis associated with a variety of inflammatory conditions. An orally active GPR4 antagonist 39c was developed, starting from a high throughput screening hit 1. The compound shows potent cellular activity and is efficacious in animal models of angiogenesis, inflammation and pain.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Drug Design , Inflammation/drug therapy , Receptors, G-Protein-Coupled/antagonists & inhibitors , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Arthritis/drug therapy , Arthritis/metabolism , COS Cells , Chlorocebus aethiops , Dose-Response Relationship, Drug , Female , HEK293 Cells , HeLa Cells , Humans , Inflammation/metabolism , Mice , Molecular Structure , Pain/drug therapy , Pain/metabolism , Rats , Rats, Sprague-Dawley , Receptors, G-Protein-Coupled/metabolism , Structure-Activity Relationship
16.
Adv Neonatal Care ; 17(5): 417-423, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28338485

ABSTRACT

BACKGROUND: The 2011 Surgeon General's Call to Action to Support Breastfeeding highlights a need for optimizing lactation-based education for all health professionals; however, few schools of nursing and medicine offer lactation-based curriculum. In an effort to address these gaps in education and care, the director of the lactation program at a large urban children's hospital developed and instituted the annual regional Human Milk Assembly (HMA), a half-day collaborative meeting of the hospital's regional and referral hospitals' neonatal intensive care unit (NICU) nursing staff, to address lactation-based educational and training needs of all participating institutions. PURPOSE: The purpose of this study was to determine whether and how participating HMA hospitals implemented the best practices surrounding human milk and breastfeeding shared by the host institution during a 10-year span of the HMA. METHODS: A prospective descriptive study was designed using an electronic web-based survey (SurveyMonkey.com) to elicit participant data. Quantitative data were analyzed using descriptive statistics whereas qualitative data were analyzed for themes via content analysis. RESULTS: Thirty-one of the 50 hospitals surveyed responded to the electronic survey for a total of 34 individual participants. Seventeen of the 22 (77%) of best practices were implemented at rates of over 50%. IMPLICATIONS FOR PRACTICE: By enabling a culture of transparency and sharing, hospital staff can be encouraged to implement best practices across a network of regional care centers. IMPLICATIONS FOR RESEARCH: This annual regional HMA could be a model for other areas and research should be conducted to evaluate such programs nationwide.


Subject(s)
Breast Feeding , Health Policy , Intensive Care Units, Neonatal , Milk, Human , Nurses, Neonatal/education , Nursing Staff, Hospital/education , Practice Guidelines as Topic , Congresses as Topic , Evidence-Based Practice , Hospitals , Humans , Infant, Newborn , Lactation , Prospective Studies , Surveys and Questionnaires
17.
Infect Immun ; 83(1): 146-60, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25312959

ABSTRACT

There are a paucity of data concerning gene products that could contribute to the ability of Moraxella catarrhalis to colonize the human nasopharynx. Inactivation of a gene (mesR) encoding a predicted response regulator of a two-component signal transduction system in M. catarrhalis yielded a mutant unable to grow in liquid media. This mesR mutant also exhibited increased sensitivity to certain stressors, including polymyxin B, SDS, and hydrogen peroxide. Inactivation of the gene (mesS) encoding the predicted cognate sensor (histidine) kinase yielded a mutant with the same inability to grow in liquid media as the mesR mutant. DNA microarray and real-time reverse transcriptase PCR analyses indicated that several genes previously shown to be involved in the ability of M. catarrhalis to persist in the chinchilla nasopharynx were upregulated in the mesR mutant. Two other open reading frames upregulated in the mesR mutant were shown to encode small proteins (LipA and LipB) that had amino acid sequence homology to bacterial adhesins and structural homology to bacterial lysozyme inhibitors. Inactivation of both lipA and lipB did not affect the ability of M. catarrhalis O35E to attach to a human bronchial epithelial cell line in vitro. Purified recombinant LipA and LipB fusion proteins were each shown to inhibit human lysozyme activity in vitro and in saliva. A lipA lipB deletion mutant was more sensitive than the wild-type parent strain to killing by human lysozyme in the presence of human apolactoferrin. This is the first report of the production of lysozyme inhibitors by M. catarrhalis.


Subject(s)
Moraxella catarrhalis/growth & development , Moraxella catarrhalis/metabolism , Muramidase/antagonists & inhibitors , Protein Kinases/metabolism , Signal Transduction , Transcription Factors/metabolism , Cell Adhesion , Cell Line , Culture Media/chemistry , Epithelial Cells/microbiology , Gene Deletion , Gene Expression Profiling , Genetic Complementation Test , Histidine Kinase , Microarray Analysis , Protein Kinases/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Saliva/immunology , Saliva/microbiology , Transcription Factors/genetics
18.
Blood ; 122(3): 313-20, 2013 Jul 18.
Article in English | MEDLINE | ID: mdl-23656729

ABSTRACT

Fetomaternal alloimmune thrombocytopenia, caused by the maternal generation of antibodies against fetal human platelet antigen-1a (HPA-1a), can result in intracranial hemorrhage and intrauterine death. We have developed a therapeutic human recombinant high-affinity HPA-1a antibody (B2G1Δnab) that competes for binding to the HPA-1a epitope but carries a modified constant region that does not bind to Fcγ receptors. In vitro studies with a range of clinical anti-HPA-1a sera have shown that B2G1Δnab blocks monocyte chemiluminescence by >75%. In this first-in-man study, we demonstrate that HPA-1a1b autologous platelets (matching fetal phenotype) sensitized with B2G1Δnab have the same intravascular survival as unsensitized platelets (190 hours), while platelets sensitized with a destructive immunoglobulin G1 version of the antibody (B2G1) are cleared from the circulation in 2 hours. Mimicking the situation in fetuses receiving B2G1Δnab as therapy, we show that platelets sensitized with a combination of B2G1 (representing destructive HPA-1a antibody) and B2G1Δnab survive 3 times as long in circulation compared with platelets sensitized with B2G1 alone. This confirms the therapeutic potential of B2G1Δnab. The efficient clearance of platelets sensitized with B2G1 also opens up the opportunity to carry out studies of prophylaxis to prevent alloimmunization in HPA-1a-negative mothers.


Subject(s)
Antibodies/therapeutic use , Recombinant Proteins/therapeutic use , Thrombocytopenia, Neonatal Alloimmune/drug therapy , Antigens, Human Platelet/immunology , Blood Platelets/immunology , Blood Vessels/pathology , Cell Survival/immunology , Female , Flow Cytometry , Humans , Immunoglobulin G/blood , Integrin beta3 , Male , Mutant Proteins/immunology , Software , Thrombocytopenia, Neonatal Alloimmune/blood , Thrombocytopenia, Neonatal Alloimmune/immunology
19.
Nucleic Acids Res ; 41(15): 7453-61, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23771141

ABSTRACT

G-quadruplexes and i-motifs are complementary examples of non-canonical nucleic acid substructure conformations. G-quadruplex thermodynamic stability has been extensively studied for a variety of base sequences, but the degree of duplex destabilization that adjacent quadruplex structure formation can cause has yet to be fully addressed. Stable in vivo formation of these alternative nucleic acid structures is likely to be highly dependent on whether sufficient spacing exists between neighbouring duplex- and quadruplex-/i-motif-forming regions to accommodate quadruplexes or i-motifs without disrupting duplex stability. Prediction of putative G-quadruplex-forming regions is likely to be assisted by further understanding of what distance (number of base pairs) is required for duplexes to remain stable as quadruplexes or i-motifs form. Using oligonucleotide constructs derived from precedented G-quadruplexes and i-motif-forming bcl-2 P1 promoter region, initial biophysical stability studies indicate that the formation of G-quadruplex and i-motif conformations do destabilize proximal duplex regions. The undermining effect that quadruplex formation can have on duplex stability is mitigated with increased distance from the duplex region: a spacing of five base pairs or more is sufficient to maintain duplex stability proximal to predicted quadruplex/i-motif-forming regions.


Subject(s)
G-Quadruplexes , Nucleotide Motifs , Oligonucleotides/genetics , Base Pairing , Base Sequence , Circular Dichroism , Humans , Hydrogen-Ion Concentration , Nucleic Acid Denaturation , Oligonucleotides/chemistry , Promoter Regions, Genetic , Temperature , Thermodynamics
20.
Infect Immun ; 82(6): 2287-99, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24643539

ABSTRACT

Colonization of the human nasopharynx by Moraxella catarrhalis is presumed to involve attachment of this bacterium to the mucosa. DNA microarray analysis was used to determine whether attachment of M. catarrhalis to human bronchial epithelial (HBE) cells in vitro affected gene expression in this bacterium. Attachment affected expression of at least 454 different genes, with 163 being upregulated and 291 being downregulated. Among the upregulated genes was one (ORF113) previously annotated as encoding a protein with some similarity to outer membrane protein A (OmpA). The protein encoded by ORF113 was predicted to have a signal peptidase II cleavage site, and globomycin inhibition experiments confirmed that this protein was indeed a lipoprotein. The ORF113 protein also contained a predicted peptidoglycan-binding domain in its C-terminal half. The use of mutant and recombinant M. catarrhalis strains confirmed that the ORF113 protein was present in outer membrane preparations, and this protein was also shown to be at least partially exposed on the bacterial cell surface. A mutant unable to produce the ORF113 protein showed little or no change in its growth rate in vitro, in its ability to attach to HBE cells in vitro, or in its autoagglutination characteristics, but it did exhibit a reduced ability to survive in the chinchilla nasopharynx. This is the first report of a lipoprotein essential to the ability of M. catarrhalis to persist in an animal model.


Subject(s)
Bacterial Outer Membrane Proteins/physiology , Moraxella catarrhalis/pathogenicity , Moraxellaceae Infections/microbiology , Nasopharyngeal Diseases/microbiology , Animals , Bacterial Adhesion/physiology , Cell Line , Chinchilla , Disease Models, Animal , Gene Expression Profiling , Gene Expression Regulation, Bacterial , Humans , Membrane Proteins/metabolism , Microbial Sensitivity Tests , Moraxella catarrhalis/drug effects , Moraxella catarrhalis/genetics , Oligonucleotide Array Sequence Analysis , Peptides/pharmacology , Protease Inhibitors/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL